Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer. Oo KK, Kamolhan T, Soni A, Thongchot S, et al. BMC Cancer 2021;21:65.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Oo KK, Kamolhan T, Soni A, Thongchot S, et al. Development of an engineered peptide antagonist against periostin to overcome doxorubicin resistance in breast cancer. BMC Cancer 2021;21:65.
PMID: 33446140